114 results about "Inflammatory bowel disease" patented technology

A method for treating inflammatory bowel disease using prolyl hydroxylase domain-containing protein (PHD) inhibitors and additional agents is described herein.

This disclosure provides methods and compositions for determining the risk of a patient being unresponsive to a therapeutic dose of anti-TNF-like ligand 1A (TL1A) antibody, as well as methods and compositions for treating inflammatory bowel disease (IBD) with a therapeutic dose of anti-TNF-like ligand 1A (TL1A) antibody.

The present invention provides, in part, novel small molecule inhibitors of PHD, having a structure according to Formula (I), and sub-formulas thereof: Formula (I) or a pharmaceutically acceptable salt thereof. The compounds provided herein can be useful for treatment or prevention of diseases including heart (e.g. ischemic heart disease, congestive heart failure, and valvular heart disease), lung (e.g., lung inflammation, pneumonia, acute lung injury, pulmonary hypertension, pulmonary fibrosis, and chronic obstructive pulmonary disease), respiratory (e.g.,respiratory infection, acute respiratory distress syndrome), liver (e.g. acute liver failure and liver fibrosis and cirrhosis), and kidney (e.g. acute kidney injury and chronic kidney disease) disease, inflammatory bowel disease (IBD), ischemic reperfusion injury (e.g., stroke), retinopathy of prematurity (ROP), bronchopulmonary dysplasia (BPD), and white matter injury (WMI).

This application relates to the field of biomedical technology and discloses the application of juniperol or its derivatives in the preparation of drugs that inhibit Drp1-mediated excessive mitochondrial division. This application verifies through in vitro and in vivo experiments that juniperol can inhibit phosphorylation at the Ser616 site of Drp1 and Drp1 mitochondrial translocation, thereby inhibiting Drp1-mediated excessive mitochondrial division. This demonstrates a good therapeutic effect on mitochondrial excessive division-related diseases such as inflammatory bowel disease, providing a new therapeutic strategy for the treatment of these diseases and possessing significant clinical implications.

The application belongs to the field of biological medicine, and particularly relates to a pharmaceutical composition for treating inflammatory bowel disease and application of the pharmaceutical composition. The disclosed pharmaceutical composition comprises anti-TNF monoclonal antibody, phosphoketolase-producing bacteria or a pharmaceutically acceptable viable bacterial preparation or extract thereof. The application comprehensively utilizes multi-dimensional data analysis and experimental verification of'microbe-immune', and finds that the phosphoketolase-producing bacteria can regulate host immune metabolic microenvironment, actively stabilize blood drug concentration of the anti-TNF monoclonal antibody and reduce immunogenicity, so as to achieve the purposes of stabilizing blood drug concentration of the anti-TNF monoclonal antibody and delaying clearance, significantly improve clinical response rate and remission rate, and is particularly suitable for a patient population with primary non-response or secondary non-response to the anti-TNF monoclonal antibody, thereby providing an effective solution for solving this clinical difficulty.

The application belongs to the technical field of new application of microorganisms, and particularly relates to an enterobacter and application of the enterobacter in improving inflammatory bowel disease. The strain is named LS-68, is preserved in the China General Microbiological Culture Collection Center, has a preservation date of October 28, 2024, and has a preservation number of CGMCC NO.32368. The strain has the ability of group movement, has strong adaptability to the intestinal environment, well tolerates the acidity of gastric juice, is sensitive to a plurality of commonly used antibiotics, and has a good improvement effect on colitis.

This invention relates to double-stranded oligonucleotides complementary to JAK1 that result in the regulation of JAK1 expression. Regulation of JAK1 expression is beneficial for a range of medical disorders, including inflammatory bowel disease, organ transplant rejection, graft-versus-host disease, multiple sclerosis, rheumatoid arthritis (RA), juvenile idiopathic arthritis, psoriasis, dermatitis, diabetic nephropathy, systemic lupus erythematosus (SLE), dry eye disease, cancer, myelofibrosis, and asthma. The invention also includes compositions comprising double-stranded oligonucleotides and therapeutic methods using double-stranded oligonucleotides.

The application belongs to the technical field of medical diagnosis assistance, and provides an inflammatory bowel disease evaluation method and system. The method obtains biological sample data of a target object, pre-processes the biological sample data to standardize each index data, calculates multiple scores representing the individual state of the target object based on the pre-processed biological sample data, and constructs a comprehensive evaluation index for quantitatively evaluating the inflammatory bowel disease of the target object based on each score. The scheme provided by the application integrates multiple index data to construct a multi-dimensional comprehensive evaluation index, which can comprehensively and accurately reflect the pathophysiological nature of inflammatory bowel disease, effectively avoiding misdiagnosis or missed diagnosis caused by single-dimensional evaluation, and providing a non-invasive, convenient and standardized technical solution for the diagnosis, disease monitoring and efficacy evaluation of inflammatory bowel disease.

A Bifidobacterium longum subsp longum produced by a method of growing the Bifidobacterium longum subsp longum in a culture medium, the culture medium containing a fructose disaccharide, FOS or combination thereof. A method for treatment or prevention of inflammatory bowel disease, celiac disease, non-celiac gluten sensitivity, gluten ataxia, dermatitis herpetiformis or wheat allergy in an individual, the method including administering a combination of (i) Bifidobacterium longum subsp longum and (ii) a fructose disaccharide, FOS or a combination thereof to the individual.

This invention provides a controlled-release pharmaceutical composition containing indigo naturalis or its main active ingredient, a method for its preparation, and its application. The controlled-release pharmaceutical composition comprises microspheres, each microsphere containing the active ingredient and one or more pharmaceutically acceptable excipients. The active ingredient includes indigo naturalis, indigo, indirubin, or any combination thereof; the microspheres are coated with an enteric outer layer. The controlled-release pharmaceutical composition provided by this invention can alleviate the symptoms of inflammatory bowel diseases, especially ulcerative colitis, and can reduce or avoid the endocytosis of the active ingredient by intestinal macrophages, thereby reducing the impact on the patient's liver. It exhibits good stability, and the controlled-release pharmaceutical composition of this invention reduces side effects while maintaining therapeutic efficacy.

To provide a composition that can suppress the decline in the barrier function of the intestinal epithelium in non-infectious inflammatory bowel disease. [Solution] An agent containing human milk oligosaccharides that suppresses the decline in the barrier function of the intestinal epithelium in non-infectious inflammatory bowel disease.

This application discloses the use of probiotics and their vesicles in the prevention or treatment of inflammatory bowel disease. The probiotic vesicles are *Ackermania myxophilus* artificial vesicles (AADV). The *Ackermania myxophilus* artificial vesicles prepared by this invention not only have better therapeutic effects but also good biocompatibility. Furthermore, the preparation process of the *Ackermania myxophilus* artificial vesicles prepared by this invention is simple and efficient, and easy to mass-produce. Therefore, it has good clinical application prospects in the treatment of inflammatory bowel disease.

This application provides a selective HDAC6 inhibitor, its preparation method, and its application, belonging to the field of medicinal chemistry. The selective HDAC6 inhibitor is a compound of Formula I or a pharmaceutically acceptable salt thereof, where R1, R2, R3, R4, R5, R6, and L are as described herein. The compound of Formula I is a highly selective histone deacetylase 6 (HDAC6) inhibitor, which can be used for diseases caused by HDAC6 abnormalities, such as inflammatory diseases (e.g., peritonitis, inflammatory bowel disease, psoriasis) and other diseases.

The present invention provides methods of diagnosing, treating, and monitoring the progression of inflammatory bowel disease in a subject, including, for example, by monitoring RORγt+Th or RORγt+Treg cell levels and treating the subject accordingly.

Novel compounds of Formula (I), and the pharmaceutically acceptable salts thereof, are inhibitors of NLRP3 and may be useful in the treatment, prevention, management, amelioration, control and suppression of diseases mediated by NLPR3. The compounds of the present invention may be useful in the treatment, prevention or management of diseases, disorders and conditions mediated by NLRP3 such as, but not limited to, obesity, gout, pseudogout, CAPS, NASH, MASH, fibrosis, heart failure, idiopathic pericarditis, atopic dermatitis, inflammatory bowel disease, Alzheimer's Disease, Parkinson's Disease, dementia with Lewy bodies (DLB), and traumatic brain injury.

The present invention relates to a method for producing an ustekinumab antibody in CHO cells. It further relates to the use of the produced antibody in the treatment of plaque psoriasis, psoriatic arthritis and inflammatory bowel disease.

The therapeutic needs of patients with IBD and / or related conditions or symptoms remain unmet, and new treatment options are needed. [Solution] This disclosure relates to a method for treating or preventing inflammatory bowel disease (IBD) in a subject in need thereof, comprising administering a composition comprising mesenchymal lineage progenitor or stem cell (MLPSC) to the subject.

The application belongs to the technical field of new use of medicines, and particularly discloses an As(III)-containing compound Darinaparsin and application thereof, and the As(III)-containing compound Darinaparsin is applied to preparation of a medicine for treating inflammatory bowel disease. The As(III)-containing compound Darinaparsin and application thereof are used to solve the defects of low response rate and easy drug resistance of the existing medicines for treating inflammatory bowel disease, and provide a new use of the As(III)-containing compound Darinaparsin, which is used for treating inflammatory bowel disease, and provide a new treatment scheme with definite curative effect and clear mechanism.

Disclosed herein are C-mannoside compounds, compositions thereof and their application as pharmaceuticals for the treatment of human disease. Methods of inhibition of FimH activity in a human subject are also provided for the treatment of diseases such as bacterial infection, Crohn's disease (CD) and Inflammatory Bowel Disease (IBD).

This invention discloses a high-performance computing-based system and method for evaluating colorectal cancer screening strategies, belonging to the field of medical information processing technology. It includes: a dual-pathway disease model module supporting both adenoma-carcinoma pathways and serrated adenoma pathways, modeled using age-dependent normal distribution progression time; an individualized risk scoring module integrating risk factors such as family history, inflammatory bowel disease, obesity, and diabetes; a screening strategy simulation module supporting combined screening strategies using different tools, employing compliance parameters specific to the Chinese urban population; a high-performance computing module using Numba JIT compilation technology for acceleration, multi-process parallel processing for further acceleration, and data structure optimization such as integer age to reduce memory usage; and a health economics evaluation module calculating indicators such as QALY, LYG, and ICER. This invention achieves significant performance improvements while maintaining model accuracy, greatly reducing simulation time for large-scale populations.

The present invention relates to pharmaceutical methods, compositions and combinations for the treatment and / or prevention of inflammatory bowel disease (IBD). In particular, the present invention relates to methods and compositions for the treatment of IBD comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof.

The novel compounds of Formula (I), and the pharmaceutically acceptable salts thereof, are NLRP3 inhibitors and may be useful in the treatment, prevention, management, improvement, control, and suppression of NLRP3-mediated diseases. The compounds of the present invention may be useful in the treatment, prevention, or management of NLRP3-mediated diseases, disorders, and conditions such as, but not limited to, obesity, gout, pseudogout, CAPS, NASH, MASH, fibrosis, osteoarthritis, atherosclerosis, heart failure, idiopathic pericarditis, myocarditis, atopic dermatitis, hidradenitis suppurativa, inflammatory bowel disease, cancer, Alzheimer's disease, Parkinson's disease, Lewy body dementia (LBD), and traumatic brain injury. (I)

The application belongs to the technical field of biotechnology, and particularly relates to an anti-TL1A nanobody and application thereof. The amino acid sequences of the complementarity determining regions CDR1, CDR2 and CDR3 of the nanobody are respectively shown as SEQ ID NO:3, SEQ ID NO:4 and SEQ ID NO:5, and the amino acid sequence of the heavy chain variable region is shown as SEQ ID NO:1. The application uses a llama natural nanobody library and combines phage display technology to successfully screen a high-affinity nanobody targeting TL1A. The antibody can specifically recognize human TL1A protein and a TL1A overexpression cell line, and has high affinity, high specificity and good physicochemical stability. Based on the characteristic of targeting TL1A, the nanobody has important application value in the precise diagnosis and targeted treatment of TL1A high-expression related diseases such as inflammatory bowel disease, rheumatoid arthritis, asthma and fibrosis, and is particularly suitable for developing a high-sensitivity in-vitro diagnostic kit and a novel biological therapeutic drug.

This invention provides an aromatic hydrocarbon receptor agonist with a benzofuran skeleton, its preparation method, and its application, belonging to the field of chemical synthetic drug technology. The compound has the structure shown in Formula I: Formula I. The small molecule compounds of this invention exhibit good agonistic activity against AHR in vitro and show good alleviating effects on psoriasis, inflammatory bowel disease, and atopic dermatitis. Some compounds show better anti-psoriasis effects than currently used clinical drugs.

The present invention provides methods of diagnosing, treating, and monitoring the progression of inflammatory bowel disease in a subject, including, for example, by monitoring RORγt +Th or RORγt +Treg cell levels and treating the subject accordingly.

This invention relates to the application of a melanin-catalase nanocomposite (MAC) targeting intestinal mucosal neutrophils in the preparation of drugs for treating inflammatory bowel disease, belonging to the field of novel applications of nanomedicine. It addresses the challenges of catalase oral delivery being easily degraded and inactivated by gastrointestinal proteases and difficult to precisely target neutrophils. This invention is the first to discover a MAC prepared by in-situ polymerization of dopamine on the surface of catalase, which can be used for the treatment of inflammatory bowel disease. This nanocomposite, through oral delivery, precisely targets intestinal mucosal infiltrating neutrophils and maintains structural stability in the gastrointestinal fluid environment, effectively protecting catalase activity. It actively targets intestinal mucosal infiltrating neutrophils through the high affinity of melanin for dopamine D2 receptors, synergistically exerting a triple effect of hydrogen peroxide decomposition, hypochlorous acid scavenging, and iron ion chelation, effectively inhibiting the formation of extracellular traps in neutrophils.

The therapeutic needs of patients with IBD and / or related conditions or symptoms remain unmet, and new treatment options are needed. [Solution] This disclosure relates to a method for treating or preventing inflammatory bowel disease (IBD) in a subject in need thereof, comprising administering a composition comprising mesenchymal lineage progenitor or stem cell (MLPSC) to the subject.